MRK241227C125000
- 0.07
- 0.000.00%
メルクのニュース一覧
中金：维持翰森制药“跑赢行业”评级 目标价21.12港元
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Boeing and 6 More Contrarian Stocks for 2025
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Dow Rallies 117 Points On Gains For NVIDIA Corp., UnitedHealth Stocks
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
BMOキャピタル・マーケッツはメルク(MRK.US)のレーティングを中立に引き下げ、目標株価を105ドルに引き下げた
BMOキャピタル・マーケッツのアナリストEvan Seigermanは$Merck & Co(MRK.US)$のレーティングを中立に引き下げ、目標株価を136ドルから105ドルに引き下げた。TipRanksのデータによると、このアナリストの最近1年間の的中率は43.9%、平均リターンは5.5%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する
Merck Downgraded by BMO Over Keytruda Concerns
Investing in Merck (NYSE:MRK) Three Years Ago Would Have Delivered You a 43% Gain
Merck & Co., Inc. (MRK) Is Attracting Investor Attention: Here Is What You Should Know
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?
Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024...
Merck: Will Record Pretax Chg Relating to Upfront Payment of $588M, or 18c/Shr, in 4Q Results >MRK
BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105
Merck & Co Analyst Ratings
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services